Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 in Advanced Chronic Leg Ischemia (ADR-04)
jRCT2073220005Phase 1Completed
- Start
- Apr 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans. Primary endpoint: Safety (occurrence of adverse events). Started Apr 2022; status: completed.
02
Drugs
ADR-001
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2073220005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073220005.